



## OPEN ACCESS

## EDITED BY

Pilar Giraldo,  
University of Zaragoza, Spain

## REVIEWED BY

Thomas J. Kean,  
University of Central Florida, United States  
Naibo Feng,  
Weifang People's Hospital, China

## \*CORRESPONDENCE

Hao Li,  
✉ lh365@163.com

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 21 August 2025

REVISED 26 November 2025

ACCEPTED 29 November 2025

PUBLISHED 16 December 2025

## CITATION

Ye X, Zheng C and Li H (2025) A transcriptomic atlas at bulk and single-cell levels identifies novel transcriptional and splicing regulators of ECM homeostasis in osteoarthritis. *Front. Genet.* 16:1690319. doi: 10.3389/fgene.2025.1690319

## COPYRIGHT

© 2025 Ye, Zheng and Li. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# A transcriptomic atlas at bulk and single-cell levels identifies novel transcriptional and splicing regulators of ECM homeostasis in osteoarthritis

Xiguang Ye<sup>1,2†</sup>, Chunyan Zheng<sup>3†</sup> and Hao Li<sup>3\*</sup>

<sup>1</sup>Hubei University of Chinese Medicine, Wuhan, Hubei, China, <sup>2</sup>Affiliated Hospital of Hubei University of Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Provincial Institute of Traditional Chinese Medicine, Wuhan, Hubei, China, <sup>3</sup>The First Clinical Medical School, Hubei University of Chinese Medicine, Wuhan, Hubei, China


Osteoarthritis (OA) is a common chronic degenerative joint disease. Chondrocytes undergo dynamic changes during the pathogenesis of OA, and the destruction of the extracellular matrix (ECM) and its homeostatic disruption are hallmarks of OA. This study explores the roles of transcriptional and alternative splicing (AS) mechanisms in regulating extracellular matrix (ECM) homeostasis in osteoarthritis (OA), using bulk and single-cell RNA-sequencing data. By analyzing two OA transcriptome datasets, we identified differentially expressed genes (DEGs) that are enriched in ECM-related pathways and constructed a regulatory network between differentially expressed transcription factors (DE TFs) and ECM-related DEGs. This revealed the potential roles of transcription factors *ELF3* and *DDIT3* in regulating the expression of *COL3A1*, *COL5A2*, and *S100A4*. Single-cell RNA-sequencing data further validated the expression patterns of *ELF3* and *DDIT3* in distinct chondrocyte subtypes. Additionally, by analyzing AS events, we identified the RNA-binding protein (RBP) *KHDRBS3* as a regulator of AS for the ECM-related gene *IL16*. Aberrant changes in these events may impact the ECM environment of chondrocytes and contribute to the pathogenesis of OA. This study, for the first time, dissects the regulatory models in OA cartilage at both transcriptional and post-transcriptional levels. These findings provide novel potential targets for early diagnosis and intervention strategies in OA.

## KEYWORDS

alternative splicing, extracellular matrix, osteoarthritis, RNA-binding protein, transcription factor

## 1 Introduction

Osteoarthritis (OA) is a common chronic degenerative joint disease and a leading cause of increased global disability and morbidity (Glyn-Jones et al., 2015). The pathogenesis of OA includes the degradation of cartilage matrix, inflammation, fibrosis, failure of cartilage repair, bone remodeling, and aging (Jiang, 2022; Vincent et al., 2022; Li et al., 2023a). During the development of OA, chondrocytes are not static but undergo continuous and complex dynamic changes (Singh et al., 2019). The extracellular matrix (ECM) is a major component of articular cartilage and is crucial for the structural maintenance, metabolic regulation, inflammatory response, and repair processes of the joint (Choi et al., 2023; Chatterjee et al.,



**FIGURE 1**  
Workflow of bioinformatic analyses in this study. Schematic workflow integrating bulk RNA-seq (GSE168505, GSE111357) and scRNA-seq (GSE169454) analyses.

2022; Hodgkinson et al., 2022; Gao et al., 2014). The destruction of the chondrocyte ECM and the disruption of its homeostasis are hallmarks of OA (Rahmati et al., 2017; Peng et al., 2021). Transcription factors (TFs), as a class of key proteins that regulate gene expression, can also participate in the pathological process of OA by influencing chondrocyte development and the homeostasis of

the ECM (Lefebvre and Dvir-Ginzberg, 2017; Neefjes et al., 2020). However, the dynamic changes of the ECM during the pathogenesis of OA, as well as the intricate regulatory networks underlying these changes, remain to be further elucidated.

Alternative splicing (AS) is the process by which pre-messenger RNA (pre-mRNA) in eukaryotes is spliced at different splice sites to

generate a variety of mature mRNA isoforms (Ule and Blencowe, 2019). Numerous studies have illustrated that abnormal AS events are implicated in a wide range of human diseases (Marasco and Kornblihtt, 2023). Recent studies have demonstrated that AS in OA is often associated with genes related to the ECM and collagen (Cai et al., 2019; Zhang et al., 2024a; Liu et al., 2024). However, few studies have systematically explored the role of abnormal AS in the development and progression of OA.

Our study demonstrates that the homeostasis imbalance of the ECM in OA is dually regulated by TFs and AS, with both mechanisms driving cartilage degeneration through complex regulatory networks. The transcription factors ELF3 and DDIT3 regulate the expression of *COL3A1*, *COL5A2*, and *S100A4*. The RNA-binding protein (RBP) KHDRBS3 modulates the AS events of *IL16*. Aberrant changes in these events may impact the ECM environment of chondrocytes and contribute to the pathogenesis of OA. These findings can provide new potential targets for the early diagnosis and intervention strategies of OA.

## 2 Materials and methods

### 2.1 Retrieval and process of public data

The overall procedures of our study are illustrated in the flow chart (Figure 1). Public sequence data files of 3 RNA-seq dataset from GSE168505 (SRP309832), GSE111357 (SRP133881) and GSE169454 were downloaded from the Sequence Read Archive (SRA), where GSE168505 and GSE169454 contain cartilage tissues from 4 OA patients and 3 healthy individuals, and GSE111357 includes hip cartilage tissues from 10 OA patients and 6 control subjects (with neck of femur fractures but no OA). SRA Run files were converted to fastq format with NCBI SRA Tool fastq-dump. The raw reads were trimmed of low-quality bases using a FASTX-Toolkit (v.0.0.13; [http://hannonlab.cshl.edu/fastx\\_toolkit/](http://hannonlab.cshl.edu/fastx_toolkit/)). Then the clean reads were evaluated using FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc>).

### 2.2 AS analysis using SUVA

The alternative splicing (AS) events and regulated alternative splicing events (RAS) between healthy controls (HC) and OA samples were defined and quantified using the alternative splicing analysis software SUVA. SUVA is a bioinformatic tool specialized in AS analysis from RNA-seq data, which detects AS events by quantifying splice site usage variation: it first defines events based on annotated genomes and RNA-seq read alignments, then calculates two key metrics—splicing ratio difference (to reflect the magnitude of splicing variation between groups) and reads proportion of SUVA AS event (pSAR, to ensure the reliability of detected events)—to filter high-confidence AS signals; it classifies AS events into five main types (Cheng et al., 2021):

- Alternative 5'splice site (alt5p/A5SS): Shares a common 3'splice site but uses alternative 5'splice sites, leading to transcripts with variable 5'exon lengths.

- Alternative 3'splice site (alt3p/A3SS): Shares a common 5'splice site but uses alternative 3'splice sites, resulting in transcripts with variable 3'exon lengths.
- Intron retention (IR): A full intron is retained in the mature transcript, corresponding to a splice site pair that is either used or unused, leading to transcripts with retained intronic sequences.
- Contain: One splice junction (SJ) is completely contained within another SJ, meaning the sequence of one SJ is a subset of another SJ's sequence.
- Overlap (olp): Two SJs have distinct splice sites but their junction sequences partially overlap, creating complex splicing patterns with shared sequence regions.

### 2.3 Co-expression analysis of differentially expressed TFs and ECM-related differential expression of genes

The software DEseq2 (Love et al., 2014), which is specifically used to analyze the differential expression of genes, was applied to screen the raw count data for differentially expressed genes (DEGs). The results were analyzed based on the fold change ( $FC \geq 2$  or  $\leq 0.5$ ) and false discovery rate ( $FDR \leq 0.05$ ) to determine whether a gene was differentially expressed. 1190 ECM-related genes were retrieved from the GO (<https://www.geneontology.org/>), KEGG (<https://www.genome.jp/kegg/>) and MatrisomeDB (<https://matrisomedb.org/>).

### 2.4 Prediction of TF motifs and TF binding sites on genes


This study systematically identified TF binding motifs using the JASPAR database (Rauluseviciute et al., 2023). The FIMO module (Grant et al., 2011) from the MEME suite was implemented for genome-wide prediction of TF binding sites, with promoter regions defined as sequences spanning from  $-1,000$  bp upstream to  $+100$  bp downstream relative to the transcription start site (TSS).

### 2.5 Functional enrichment analysis

To identify functional categories of genes, we employed the clusterProfiler package (v4.6.2) (Wu et al., 2021), which enabled us to determine Gene Ontology (GO) terms and KEGG pathways.

### 2.6 Co-expression analysis of splicing ratio of ECM-related RAS and expression of differentially expressed RBPs

Then expression profile of differentially expressed RBPs (DE RBPs) were filtered out from all DEGs according to a catalogue of 2,141 RBPs of human was retrieved from previous report (Castello et al., 2012; Castello et al., 2016; Gerstberger et al., 2014; Hentze et al., 2018). The regulated AS events located in ECM-related genes (ECM-RAS) were screened and analyzed. The co-disturbed network between the expression of DE RBPs and the splicing ratio of ECM-RAS was constructed, with Spearman's  $p$ value  $\leq 0.05$  being retained.



## 2.7 Other statistical analysis

Principal component analysis (PCA) analysis was performed by R package factextra (<https://cloud.r-project.org/package=factextra>) to show the clustering of samples with the first two components. After normalizing the reads by TPM (Tags Per Million) of each gene in samples, in house-script (sogen) was used for visualization of next-generation sequence data and genomic annotations. The pheatmap package (<https://cran.r-project.org/web/packages/pheatmap/index.html>) in R was used to perform the clustering based on Euclidean distance.

## 3 Results


### 3.1 Analysis of DEGs in OA and control samples

PCA was performed based on the expression levels of all detected genes to explore the global expression pattern. The PCA clustering outcomes indicated that the OA and control groups

were distinctly separated along the first principal component (Figure 2A), suggesting significant differences in their global gene expression pattern. We then screened the data for DEGs, which revealed 1760 upregulated genes and 1,385 downregulated genes in Dataset 1 (GSE168505), and 802 upregulated genes and 1,021 downregulated genes in Dataset 2 (GSE111357) (Figure 2B). Gene ontology biological process (GO-BP) analysis indicated enriched terms in which the DEGs were involved. The results showed that in Dataset 1, the upregulated DEGs were mainly related to chemotaxis and cell adhesion, while the downregulated DEGs were primarily associated with mRNA splicing and limb morphogenesis (Supplementary Figure S1A,B). In Dataset 2, the biological processes in the upregulated DEGs mainly involved extracellular matrix organization and extracellular structure organization, while those in the downregulated DEGs were linked to response to biotic stimulus, regulation of inflammatory response, and cell adhesion (Supplementary Figure S1C,D). These findings suggest that the aforementioned biological pathways may play important roles in the pathogenesis of OA.

Considering that the expression changes of ECM-related genes may serve as a hallmark of OA, we further performed an





overlap analysis between the 147 overlapping DEGs identified in the two RNA-seq datasets and a list of 1,190 known ECM-related genes. A total of 31 ECM-related DEGs were obtained, with 26 genes commonly upregulated and 5 genes commonly downregulated in both datasets (Figure 2C). The detailed list of genes is provided in Supplementary Table S1, and the changes in gene expression levels are depicted in the heatmap (Figure 2D). The biological processes involved in the 31 ECM-related DEGs mainly include ECM organization, extracellular structure organization, ECM glycoproteins, ECM regulators, and collagen fibril organization (Figure 2E). It can be inferred that these genes are primarily associated with the composition and regulation of the ECM.

### 3.2 Construction of the regulatory network of differentially expressed TFs-ECM-related genes in OA

To uncover the regulatory mechanisms of the expression of ECM-related genes in OA, we analyzed the differentially expressed transcription factors (DE TFs) that were commonly identified in the OA and HC groups across the two datasets. Heatmaps were used to display their expression levels in each sample. It was observed that, compared to the HC group, the transcription factor genes *PKNOX2*, *DDIT3*, *MAFF*, *BCL6*, and *ELF3* were significantly downregulated in OA, while only the transcription factor *HEY1* was upregulated in OA (Figure 3A). By conducting correlation analyses between DE TFs and ECM-related DEGs, we constructed a co-expression network of DE TFs and ECM-related DEGs (Figure 3B). The transcription factor gene *ELF3* occupies a central position, interacting with multiple ECM-related DEGs (such as *S100A4*, *ANGPTL1*, *COL5A2*, *COL21A1*, etc.), and it is also regulated by transcription factors *BCL6*, *DDIT3*, and *PKNOX2*. Subsequently, we employed bioinformatics prediction to analyze the potential binding sites of *ELF3* in the promoter regions of *COL21A1* and *COL3A1*. Motif analysis revealed a potential *ELF3* binding site in the promoter region of *COL21A1*, with the sequence 5'-CAATTCCTC-3'; a potential *ELF3* binding site was also identified in the promoter

region of *COL3A1*, with the sequence 5'-CACTTCCTC-3' (Figure 3C).


### 3.3 Analysis of ECM-related splicing events in OA

To further explore the role of AS in the pathogenesis of OA, we utilized the SUVA to identify AS events in the two datasets. Initially, we sought to identify RAS events between HC and OA groups. Altogether, 568 and 1517 RAS events were identified by SUVA in Dataset 1 and Dataset 2, respectively, with alternative 5'splice sites (alt5p) and alternative 3'splice sites (alt3p) being the predominant types (Figure 4A). Corresponding to classical splicing events, they were predominantly cassette exons and alternative 5'splice site selection (A5SS) (Supplementary Figure S2A). The GO-BP analysis of these regulated alternative splicing genes (RASGs) showed that they were enriched in processes related to RNA splicing and cell structure (Supplementary Figure S2B). Further overlap analysis revealed that 37 RAS events were present in both datasets (Figure 4B; Supplementary Table S2). This indicates that these AS events may have a certain degree of conservation in the regulation of OA pathogenesis. The heatmap displays the splicing ratios of these 37 RAS events in each sample from the two datasets and annotates their types. Subsequently, 3 ECM-RAS events were identified, involving RASGs *COL6A3*, *IL16*, and *RGCC* (Figure 4C). In OA, *IL16* tends to utilize the proximal 5'splice site, while *COL6A3* and *RGCC* preferentially select the distal 3'splice site (Figure 4D; Supplementary Figure S2C).

### 3.4 Identification of RBPs regulating ECM-related splicing events in OA


AS, as a crucial post-transcriptional regulatory mechanism, is significantly influenced by RBPs that determine the final form of mRNA and the resulting protein products. We conducted predictive analysis of the upstream RBPs involved in ECM-related splicing





the cell clusters based on known cell-specific markers. This process identified eight distinct cell clusters: fibrocartilage cells (FC), effector chondrocytes (EC), homeostatic chondrocytes (HomC), hypertrophic chondrocytes (HTC), pre-hypertrophic chondrocytes (preHTC), proliferating chondrocytes (ProC), regulatory chondrocytes (RegC), and an unknown type





**FIGURE 6** Single-cell Validation of Key Regulators. **(A)** UMAP projection of chondrocyte subtypes: Fibrochondrocytes (FC), Homeostatic (HomC), Hypertrophic (HTC), Pre-hypertrophic (preHTC), Proliferating (ProC), Regulatory (RegC), Effector (EC), and Unknown. **(B)** Dot plot showing conserved DE TFs across bulk and single-cell data. **(C)** Dot plot displaying overlapping ECM-related DEGs expression in chondrocyte subtypes.



(Unknown) (Figure 6A). The UMAP analysis reveals a distinct distribution of chondrocytes in the low-dimensional space for OA compared to normal samples. Specifically, the proportions of HomC, HTC and RegC are reduced in OA, while the proportions of FC, EC, preHTC and ProC are increased (Figure 6A). These differences may be related to the pathogenesis of OA and the changes in chondrocyte states.

By analyzing the DE TFs between the two groups of samples in the scRNA-seq dataset and within each type of chondrocyte, and intersecting them with the DE TFs identified in the bulk RNA-seq dataset, we obtained four overlapping TF genes, specifically *ELF3*, *HEY1*, *MAFF*, and *DDIT3* (Figure 6B). Among them, *MAFF* and *DDIT3* showed consistent expression trends in both scRNA-seq and bulk RNA-seq data, with overall downregulation in OA. *DDIT3* was downregulated in the RegC, ProC, HTC, HomC, and FC types in OA, while it was upregulated in preHTC. The scRNA-seq data analysis revealed upregulation of *ELF3* in preHTC cells in OA, while bulk RNA-seq data show that the overall expression of *ELF3* is downregulated in OA patients (Supplementary Figure S3A–C). This apparent inconsistency is primarily driven by cell-type-specific expression patterns and variations in chondrocyte subtype proportions, rather than disease-stage heterogeneity or technical bias. Bulk RNA-seq reflects the average expression of genes across all cell types in cartilage tissue, so the overall downregulation signal likely arises from the combined effect of gene expression changes in the majority of chondrocyte subtypes; in contrast, single-cell RNA-seq captures subtype-specific expression, thus identifying the unique upregulation of *ELF3*/*DDIT3* in preHTC. This difference highlights the advantage of single-cell resolution in dissecting gene expression heterogeneity that is masked in bulk analysis. This demonstrates that single-cell sequencing data can more precisely localize gene expression trends in different cell types.

Similarly, by performing overlap analysis between ECM-related genes identified in the scRNA-seq dataset and those in the bulk RNA-seq dataset, a total of 15 overlapping ECM-related genes were obtained. Among them, genes such as *S100A4*, *SPARC*, *COL5A2*, and *COL3A1* showed certain expression differences in various types of chondrocytes between the OA and normal groups, with upregulation in OA (Figure 6C), consistent with the bulk RNA-seq data.

In conjunction with the co-expression network of DE TFs and ECM-related genes, we speculate that the transcription factor *ELF3* may specifically regulate the transcription of ECM-related genes such as *COL3A1*, *COL5A2*, and *S100A4* in preHTC, while the transcription factor *DDIT3* may regulate the transcription of *COL5A2*, together mediating the pathogenesis of OA.

## 4 Discussion

This study elucidates the dynamic changes in the ECM during the progression of OA and explores the underlying complex regulatory networks, with a focus on the roles of transcriptional regulation and AS—a dual regulatory perspective rarely integrated in prior OA research. By analyzing two sets of OA transcriptome data, it was found that the DEGs were enriched in ECM-related pathways. We constructed a regulatory network of DE TFs-ECM-related DEGs, highlighting the potential regulatory roles of

transcription factors *ELF3* and *DDIT3* in modulating the expression of ECM-related genes such as *COL3A1*, *COL5A2*, and *S100A4*. Notably, unlike previous studies that only reported *ELF3*'s general pro-degradative effect in articular chondrocytes (Otero et al., 2012; Zhang et al., 2024b; Otero et al., 2017), our scRNA-seq data further revealed that *ELF3* is specifically upregulated in preHTC—linking its regulation of *COL3A1*/*COL5A2*/*S100A4* to the preHTC-to-HTC differentiation axis, a process central to cartilage mineralization and OA progression. Additionally, our analysis of AS events identified *KHDRBS3* as a regulator of the AS of the ECM-related gene *IL16*. While *KHDRBS3* is known to regulate AS in tumors, its role in OA cartilage has never been reported previously. This fills a critical gap in understanding how RBPs mediate post-transcriptional regulation of ECM-related inflammation in OA.

Gene expression analysis demonstrated significant differences in the expression of ECM-related genes between OA and HC groups. The abnormal fluctuations in ECM-related gene expression may drive metabolic disturbances in chondrocytes and the abnormal activation of matrix-degrading enzymes (Hering, 1999; Kim et al., 2024; Arra and Abu-Amer, 2023). The continuous disruption of ECM homeostasis leads to the destruction of cartilage integrity and the loss of mechanical buffering functions (Choi et al., 2023; Chatterjee et al., 2022), confirming that ECM disruption and imbalance are key factors in OA progression. In the analysis of TFs, *ELF3*, an epithelial-specific member of the ETS transcription factor family, is involved in regulating the remodeling of the ECM (Otero et al., 2012; Zhang et al., 2024b; Otero et al., 2017). It has been reported that the expression of *ELF3* is upregulated in OA cartilage (Otero et al., 2017; Wondimu et al., 2018), which is consistent with our scRNA-seq data analysis results—but our single-cell data further clarifies that this upregulation is restricted to preHTC, rather than a global change across all chondrocyte subtypes. *HEY1* acts as a negative regulator of osteoclast differentiation and plays a key role in bone metabolism (Rutkowski et al., 2016; Jin et al., 2022). *DDIT3* is associated with endoplasmic reticulum stress, autophagy and inflammatory responses in OA (Yu et al., 2022; Huang et al., 2024; Yan et al., 2024). *DDIT3* has been identified as one of the definitive marker genes for HomC, and the expression of HomC in OA cartilage is significantly lower than that in healthy cartilage (Huang et al., 2025), which is consistent with our analysis results. *BCL6* can alleviate *IL-1 $\beta$* -induced OA progression by enhancing the transcription of *GPR61* (Zeng et al., 2025). A previous study has shown that the percentage of follicular helper T cells in patients with OA is relatively high. Follicular helper T cells induce B cells to produce immunoglobulins and express various genes (such as *BCL6*), and the expression of follicular helper T cells is positively correlated with the disease activity of OA (Chen et al., 2023). *MAFF*, a key transcription factor related to inflammation and lipid metabolism, is significantly downregulated in OA (Cao et al., 2022), although its specific mechanisms remain unclear. *PKNOX2* is involved in cell growth, differentiation, and apoptosis (Li et al., 2023b), but no studies have yet linked it to OA.

Phenotypic changes in chondrocytes are a key factor leading to OA-related cartilage destruction. Using the scRNA-seq dataset GSE169454, we identified various chondrocyte subtypes that exhibit distinct and differential functional characteristics during the OA pathological process. Among them, FCs possess strong

immunogenicity, not only highly expressing genes associated with poor outcomes but also having the ability to promote angiogenesis; these properties may collectively drive OA progression (Hu et al., 2022). The transition from normal cartilage (predominantly hyaline cartilage) to late-stage OA cartilage (dominated by FCs) further indicates the decline in normal cartilage function and the shift toward an abnormally proliferative fibrotic phenotype during OA progression (Pan et al., 2024). ECs are in the early stage of chondrogenic differentiation, with core functions of exerting immune effects and inducing tissue inflammation. They exhibit a significant role during OA progression and may be involved in processes such as disease development, tissue repair, or biological adaptation; their functional regulation tends to be associated with the TCA cycle, glycolysis, as well as lipid and amino acid metabolism (Hu et al., 2022; Chen et al., 2024). HomCs are highly similar to classical chondrocytes, remaining in a quiescent and fully differentiated state. They are the main contributors to ECM deposition, and due to their enrichment in circadian rhythm-regulating genes, they may play a key regulatory role in the circadian clock system of OA cartilage (Gan et al., 2021). PreHTCs have the ability to initiate and regulate the process of hypertrophic differentiation, serving as an important link between normal chondrocyte differentiation and pathological hypertrophy (Ji et al., 2019). HTCs are morphologically characterized by large size and absence of cell division, and they can regulate the mineralization of the surrounding matrix. Their presence further attracts blood vessels and osteocytes to invade cartilage tissue; subsequent cell apoptosis and calcium deposition ultimately accelerate the pathological progression of human OA (Ji et al., 2019). ProCs are flat and columnar, mainly distributed in the proliferative zone of the growth plate, with spatial differences in function: the upper-layer ProCs have the potential to inhibit hypertrophic differentiation, while the lower-layer ProCs (adjacent to preHTCs and HTCs) promote hypertrophic differentiation (Ji et al., 2019). RegCs are widely distributed throughout the entire process of chondrogenic differentiation, highly expressing genes related to immune responses, inflammatory responses, and responses to endogenous stimuli. Abnormal inflammatory responses can disrupt the activity of RegCs, thereby impairing cartilage tissue homeostasis and leading to damage to cartilage structure and joint function (Ji et al., 2019).

According to the DE TFs-ECM-related DEGs regulatory network and the verification analysis of scRNA-seq, we speculate that ELF3 and DDIT3 may influence the ECM of chondrocytes in preHTC by regulating the transcription of *COL3A1*, *COL5A2*, and *S100A4*. This regulatory role is particularly relevant to OA pathogenesis, as preHTC and their differentiation into HTC are central to cartilage degeneration: HTC are morphologically distinct, non-proliferative chondrocytes that regulate matrix mineralization, and their presence promotes vascular and osteoclast invasion into cartilage, followed by chondrocyte apoptosis and calcium deposition—ultimately accelerating OA progression (Ji et al., 2019). PreHTC, as the precursors of HTC, directly control the initiation of hypertrophic differentiation (Ji et al., 2019). In OA, articular cartilage responds to injury by shifting toward a degradative, hypertrophic-like state, characterized by abnormal ECM synthesis and elevated collagenase activity, and chondrocyte hypertrophy itself induces chondrocyte damage (Singh et al., 2019). The three target genes of ELF3 and DDIT3 further underscore their

functional relevance to ECM homeostasis. *COL3A1* is highly expressed in fibrocartilage and pre-hypertrophic chondrocytes, which is consistent with the results of our analysis, and it maintains collagen homeostasis and contributes to ECM flexibility and elasticity (Li et al., 2022; Zhang et al., 2021). *COL5A2* indispensable for collagen fibril assembly, a process critical for maintaining the structural integrity of the ECM (Sh et al., 2024). *S100A4*, a well-characterized marker of fibroblasts (Simonds et al., 2022), can promote chondrocyte hypertrophy by stimulating MMP13 signaling and participates in ECM remodeling (Yammani et al., 2009). Collectively, these genes are essential for preserving ECM structure, regulating ECM function, and mediating interactions between chondrocytes and their surrounding matrix. However, their expression patterns and functional roles in specific chondrocyte subtypes (e.g., preHTC, HTC) remain incompletely characterized in existing literature. Integrating our findings, we propose that the transcription of *COL3A1*, *COL5A2*, and *S100A4* is tightly regulated by ELF3 and DDIT3. Dysregulation of these TFs (e.g., abnormal upregulation of ELF3 in preHTC or downregulation of DDIT3 in HomC) would disrupt the expression of these ECM-related genes, altering the ECM microenvironment surrounding chondrocytes. This perturbation, in turn, impairs chondrocyte function and phenotypic stability, creating a feedforward loop that drives cartilage degeneration and OA development. Based on these analyses, we speculate that ELF3 holds potential as therapeutic targets for OA, but attention must be paid to the potential risks of non-specific regulation. As an epithelium-specific member of the ETS transcription factor family, ELF3 functions are not limited to cartilage tissue (Otero et al., 2017); if ELF3 inhibition for OA fails to achieve cartilage specificity, its normal roles in other epithelial tissues or development-related pathways may be disrupted, thereby triggering potential functional abnormalities.

In terms of AS, the RAS events identified in our study were significantly enriched in RNA splicing and cell structure-related processes, which are closely related to the pathogenesis of OA. These abnormalities may lead to the dysfunction of chondrocytes and the inability to maintain the homeostasis of the ECM. Abnormalities in cell structure-related processes can also affect the morphology and function of chondrocytes, weaken their protective effect on the joints, and promote the development of OA. We identified three ECM-related genes with specific splicing alterations in OA. Among them, *COL6A3* may be involved in the regulation of the structural composition and mechanical properties of cartilage (Bloks et al., 2024). Variations in *COL6A3* can affect chondrocyte phenotypes and the expression of ECM-related genes in OA (Bloks et al., 2024). *IL16* is a pro-inflammatory cytokine that regulates OA progression as a direct target of Novel-miR-81 (Luo et al., 2024). *RGCC* is a cell cycle regulator (Guo et al., 2021), and its relationship with OA remains unclear. By constructing an RBPs-ECM-RAS network, we further identified KHDRBS3 as a potential regulator of the AS of the ECM-related gene *IL16*. Regarding KHDRBS3, it is a member of the STAR family and is primarily involved in regulating RNA alternative splicing, export, and stability, and a large number of studies have shown that it affects tumorigenesis by regulating the AS of mRNA (Wu et al., 2019; Zhao et al., 2023). According to our analytical results, we hypothesize that KHDRBS3 may promote *IL16*'s utilization of the proximal 5' splice site—which typically generates an

isoform with a truncated or altered N-terminal region. This (truncation or alteration) can affect protein localization, dimerization, or binding to downstream receptors (Song et al., 2023)—and may consequently produce a truncated, more active IL16 isoform. Such an isoform could then amplify IL16-mediated inflammatory signaling and disrupt ECM homeostasis. While experimental verification is still needed, KHDRBS3 could thus be speculated to have potential as an OA therapeutic target—its ability to specifically regulate *IL16* alternative splicing (a pro-inflammatory factor in OA) may allow targeted modulation of OA-related inflammation without fully ablating IL16's physiological functions, though risks may include unintended effects on the splicing of other genes due to its pleiotropic roles in RNA metabolism.

In conclusion, our study systematically explores the transcriptional and AS regulatory mechanisms related to ECM in OA through the integrated analysis of bulk and single-cell transcriptome data—this is the first study in OA to combine these two omics layers at single-cell resolution to dissect coordinated ECM regulatory networks. We found significant differences in the overall gene expression patterns between OA and normal samples, identified multiple DEGs, DE TFs, and RAS events, constructed relevant regulatory networks, and validated the expression patterns of key molecules at the single-cell level, providing a multidimensional perspective and rich data support for a deeper understanding of the pathogenesis of OA.

However, this study also has certain limitations. In terms of data, although we integrated multiple public datasets, these datasets may be influenced by factors such as sample origin and experimental methods, potentially introducing heterogeneity that could interfere with the accuracy and reliability of the analysis results. The limited sample size in the datasets may also fail to comprehensively cover all pathological changes and individual variations in the complex disease of OA, restricting the universality and representativeness of the findings. In terms of the depth of mechanistic research, although we identified key TFs, RBPs, and related genes, our understanding of their specific molecular mechanisms and signaling pathways in OA pathogenesis remains limited. For example, how these molecules interact with each other, how they affect chondrocyte proliferation, differentiation, and apoptosis, and how they interact with other cell types to collectively regulate OA development all require further in-depth investigation. Additionally, all conclusions in this study are derived from bioinformatic analysis of public transcriptome data, and lack experimental validation in *in vitro* or *in vivo* models. To address this, follow-up experiments could be designed as follows: (1) *In vitro*, use siRNA or overexpression plasmids to knock down or overexpress *ELF3*, *DDIT3*, and *KHDRBS3* in primary human articular chondrocytes induced by IL-1 $\beta$  (to mimic OA-like pathological conditions), then detect changes in the expression of downstream target genes (*COL3A1*, *COL5A2*, *S100A4*) via qPCR/Western blot and changes in *IL16* AS patterns via RT-PCR; (2) *In vivo*, construct OA mouse models (e.g., destabilization of the medial meniscus, DMM); and perform chondrocyte-specific knockout of *ELF3* or *KHDRBS3*, then evaluate cartilage degeneration via histological staining (Safranin O-Fast Green) and assess changes in ECM-related gene expression and AS events in cartilage tissue to verify the functional roles of these key molecules in OA progression.

## Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

## Author contributions

XY: Conceptualization, Methodology, Writing – original draft, Writing – review and editing. CZ: Data curation, Investigation, Methodology, Project administration, Writing – original draft. HL: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Software, Writing – original draft, Writing – review and editing.

## Funding

The author(s) declared that financial support was not received for this work and/or its publication.

## Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fgene.2025.1690319/full#supplementary-material>



## References

- Arra, M., and Abu-Amer, Y. (2023). Cross-talk of inflammation and chondrocyte intracellular metabolism in osteoarthritis. *Osteoarthr. Cartil.* 31 (8), 1012–1021. doi:10.1016/j.joca.2023.04.003
- Bloks, N. G., Harissa, Z., Mazzini, G., Adkar, S. S., Dicks, A. R., Hajmoussa, G., et al. (2024). A damaging COL6A3 variant alters the MIR31HG-Regulated response of chondrocytes in neocartilage organoids to hyperphysiologic mechanical loading. *Adv. Sci. (Weinh)* 11 (36), e2400720. doi:10.1002/adv.202400720
- Cai, L., Brophy, R. H., Tycksen, E. D., Duan, X., Nunley, R. M., and Rai, M. F. (2019). Distinct expression pattern of periostin splice variants in chondrocytes and ligament progenitor cells. *Faseb J.* 33 (7), 8386–8405. doi:10.1096/fj.201802281R
- Cao, H., Fu, Y., Zhang, Z., and Guo, W. (2022). Unbiased transcriptome mapping and modeling identify candidate genes and compounds of osteoarthritis. *Front. Pharmacol.* 13, 888533. doi:10.3389/fphar.2022.888533
- Castello, A., Fischer, B., Eichelbaum, K., Horos, R., Beckmann, B. M., Strein, C., et al. (2012). Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. *Cell* 149 (6), 1393–1406. doi:10.1016/j.cell.2012.04.031
- Castello, A., Fischer, B., Frese, C. K., Horos, R., Alleaume, A. M., Foehr, S., et al. (2016). Comprehensive identification of RNA-Binding domains in human cells. *Mol. Cell* 63 (4), 696–710. doi:10.1016/j.molcel.2016.06.029
- Chatterjee, M., Muljadi, P. M., and Andarawis-Puri, N. (2022). The role of the tendon ECM in mechanotransduction: disruption and repair following overuse. *Connect. Tissue Res.* 63 (1), 28–42. doi:10.1080/03080207.2021.1925663
- Chen, Z., Wang, W., and Hua, Y. (2023). Identification and validation of BCL6 and VEGFA as biomarkers and ageing patterns correlating with immune infiltrates in OA progression. *Sci. Rep.* 13 (1), 2558. doi:10.1038/s41598-023-28000-9
- Chen, B., Sun, Y., Xu, G., Jiang, J., Zhang, W., Wu, C., et al. (2024). Role of crosstalk between synovial cells and chondrocytes in osteoarthritis. *Exp. Ther. Med.* 27 (5), 201. doi:10.3892/etm.2024.12490
- Cheng, C., Liu, L., Bao, Y., Yi, J., Quan, W., Xue, Y., et al. (2021). SUVA: splicing site usage variation analysis from RNA-seq data reveals highly conserved complex splicing biomarkers in liver cancer. *RNA Biol.* 18 (Suppl. 1), 157–171. doi:10.1080/15476286.2021.1940037
- Choi, S. H., Lee, K., Han, H., Mo, H., Jung, H., Ryu, Y., et al. (2023). Prochondrogenic effect of decellularized extracellular matrix secreted from human induced pluripotent stem cell-derived chondrocytes. *Acta Biomater.* 167, 234–248. doi:10.1016/j.actbio.2023.05.052
- Gan, Y., He, J., Zhu, J., Xu, Z., Wang, Z., Yan, J., et al. (2021). Spatially defined single-cell transcriptional profiling characterizes diverse chondrocyte subtypes and nucleus pulposus progenitors in human intervertebral discs. *Bone Res.* 9 (1), 37. doi:10.1038/s41413-021-00163-z
- Gao, Y., Liu, S., Huang, J., Guo, W., Chen, J., Zhang, L., et al. (2014). The ECM-cell interaction of cartilage extracellular matrix on chondrocytes. *Biomed. Res. Int.* 2014, 648459. doi:10.1155/2014/648459
- Gerstberger, S., Hafner, M., and Tuschl, T. (2014). A census of human RNA-binding proteins. *Nat. Rev. Genet.* 15 (12), 829–845. doi:10.1038/nrg3813
- Glyn-Jones, S., Palmer, A. J. R., Agricola, R., Price, A. J., Vincent, T. L., Weinans, H., et al. (2015). Osteoarthr. *Lancet* 386 (9991), 376–387. doi:10.1016/S0140-6736(14)60802-3
- Grant, C. E., Bailey, T. L., and Noble, W. S. (2011). FIMO: scanning for occurrences of a given motif. *Bioinformatics* 27 (7), 1017–1018. doi:10.1093/bioinformatics/btr064
- Guo, Z., Chen, M., Chao, Y., Cai, C., Liu, L., Zhao, L., et al. (2021). RGCC balances self-renewal and neuronal differentiation of neural stem cells in the developing mammalian neocortex. *EMBO Rep.* 22 (9), e51781. doi:10.15252/embr.202051781
- Hentze, M. W., Castello, A., Schwarzl, T., and Preiss, T. (2018). A brave new world of RNA-binding proteins. *Nat. Rev. Mol. Cell Biol.* 19 (5), 327–341. doi:10.1038/nrm.2017.130
- Hering, T. M. (1999). Regulation of chondrocyte gene expression. *Front. Biosci.* 4, D743–D761. doi:10.2741/hering
- Hodgkinson, T., Kelly, D. C., Curtin, C. M., and O'Brien, F. J. (2022). Mechanosignalling in cartilage: an emerging target for the treatment of osteoarthritis. *Nat. Rev. Rheumatol.* 18 (2), 67–84. doi:10.1038/s41584-021-00724-w
- Hu, X., Li, Z., Ji, M., Lin, Y., Chen, Y., and Lu, J. (2022). Identification of cellular heterogeneity and immunogenicity of chondrocytes via single-cell RNA sequencing technique in human osteoarthritis. *Front. Pharmacol.* 13, 1004766. doi:10.3389/fphar.2022.1004766
- Huang, J., Zhou, J., Xue, X., Dai, T., Zhu, W., Jiao, S., et al. (2024). Identification of aging-related genes in diagnosing osteoarthritis via integrating bioinformatics analysis and machine learning. *Aging (Albany NY)* 16 (1), 153–168. doi:10.18632/aging.205357
- Huang, C., Zeng, B., Zhou, B., Chen, G., Zhang, Q., Hou, W., et al. (2025). Single-cell transcriptomic analysis of chondrocytes in cartilage and pathogenesis of osteoarthritis. *Genes Dis.* 12 (2), 101241. doi:10.1016/j.gendis.2024.101241
- Ji, Q., Zheng, Y., Zhang, G., Hu, Y., Fan, X., Hou, Y., et al. (2019). Single-cell RNA-seq analysis reveals the progression of human osteoarthritis. *Ann. Rheum. Dis.* 78 (1), 100–110. doi:10.1136/annrheumdis-2017-212863
- Jiang, Y. (2022). Osteoarthritis year in review 2021: biology. *Osteoarthr. Cartil.* 30 (2), 207–215. doi:10.1016/j.joca.2021.11.009
- Jin, F., Zhu, Y., Liu, M., Wang, R., Cui, Y., Wu, Y., et al. (2022). Babam2 negatively regulates osteoclastogenesis by interacting with Hey1 to inhibit Nfatc1 transcription. *Int. J. Biol. Sci.* 18 (11), 4482–4496. doi:10.7150/ijbs.72487
- Kim, J., Ryu, G., Seo, J., Go, M., Kim, G., Yi, S., et al. (2024). 5-aminosalicylic acid suppresses osteoarthritis through the OSCAR-PPAR $\gamma$  axis. *Nat. Commun.* 15 (1), 1024. doi:10.1038/s41467-024-45174-6
- Lefebvre, V., and Dvir-Ginzberg, M. (2017). SOX9 and the many facets of its regulation in the chondrocyte lineage. *Connect. Tissue Res.* 58 (1), 2–14. doi:10.1080/03080207.2016.1183667
- Li, Z., Ye, D., Dai, L., Xu, Y., Wu, H., Luo, W., et al. (2022). Single-cell RNA sequencing reveals the difference in human normal and degenerative nucleus pulposus tissue profiles and cellular interactions. *Front. Cell Dev. Biol.* 10, 910626. doi:10.3389/fcell.2022.910626
- Li, C., Wei, P., Wang, L., Wang, Q., Wang, H., and Zhang, Y. (2023a). Integrated analysis of transcriptome changes in osteoarthritis: gene expression, pathways and alternative splicing. *Cartilage* 14 (2), 235–246. doi:10.1177/19476035231154511
- Li, M., Liu, Q., Xie, S., Fu, C., Li, J., Tian, C., et al. (2023b). LncRNA TCONS\_00323213 promotes myogenic differentiation by interacting with PKNOX2 to upregulate MyoG in porcine satellite cells. *Int. J. Mol. Sci.* 24 (7), 6773. doi:10.3390/ijms24076773
- Liu, Q., Han, M., Wu, Z., Fu, W., Ji, J., Liang, Q., et al. (2024). DDX5 inhibits hyaline cartilage fibrosis and degradation in osteoarthritis via alternative splicing and G-quadruplex unwinding. *Nat. Aging* 4 (5), 664–680. doi:10.1038/s43587-024-00624-0
- Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15 (12), 550. doi:10.1186/s13059-014-0550-8
- Luo, Z., Han, Q., Lu, J., Ouyang, X., Fan, Y., Liu, Y., et al. (2024). IL16 regulates osteoarthritis progression as a target gene of Novel-miR-81. *Cartilage* 15 (2), 175–183. doi:10.1177/19476035231168387
- Marasco, L. E., and Kornblihtt, A. R. (2023). The physiology of alternative splicing. *Nat. Rev. Mol. Cell Biol.* 24 (4), 242–254. doi:10.1038/s41580-022-00545-z
- Neefjes, M., van Caam, A. P. M., and van der Kraan, P. M. (2020). Transcription factors in cartilage homeostasis and osteoarthritis. *Biol. (Basel)* 9 (9), 290. doi:10.3390/biology9090290
- Otero, M., Plumb, D. A., Tsuchimochi, K., Dragomir, C. L., Hashimoto, K., Peng, H., et al. (2012). E74-like factor 3 (ELF3) impacts on matrix metalloproteinase 13 (MMP13) transcriptional control in articular chondrocytes under proinflammatory stress. *J. Biol. Chem.* 287 (5), 3559–3572. doi:10.1074/jbc.M111.265744
- Otero, M., Peng, H., Hachem, K. E., Culley, K. L., Wondimu, E. B., Quinn, J., et al. (2017). ELF3 modulates type II collagen gene (COL2A1) transcription in chondrocytes by inhibiting SOX9-CBP/p300-driven histone acetyltransferase activity. *Connect. Tissue Res.* 58 (1), 15–26. doi:10.1080/03080207.2016.1200566
- Pan, B., Yao, P., Ma, J., Lin, X., Zhou, L., Lin, C., et al. (2024). Identification of key biomarkers related to fibrocartilage chondrocytes for osteoarthritis based on bulk, single-cell transcriptomic data. *Front. Immunol.* 15, 1482361. doi:10.3389/fimmu.2024.1482361
- Peng, Z., Sun, H., Bunpetch, V., Koh, Y., Wen, Y., Wu, D., et al. (2021). The regulation of cartilage extracellular matrix homeostasis in joint cartilage degeneration and regeneration. *Biomaterials* 268, 120555. doi:10.1016/j.biomaterials.2020.120555
- Rahmati, M., Nalesso, G., Mobasheri, A., and Mozafari, M. (2017). Aging and osteoarthritis: central role of the extracellular matrix. *Ageing Res. Rev.* 40, 20–30. doi:10.1016/j.arr.2017.07.004
- Rauluseviciute, I., Riudavets-Puig, R., Blanc-Mathieu, R., Castro-Mondragon, J. A., Ferenc, K., Kumar, V., et al. (2023). JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. *Nucleic Acids Res.* 52 (D1), D174–D182. doi:10.1093/nar/gkad1059
- Rutkowski, T. P., Kohn, A., Sharma, D., Ren, Y., Mirando, A. J., and Hilton, M. J. (2016). HES factors regulate specific aspects of chondrogenesis and chondrocyte hypertrophy during cartilage development. *J. Cell Sci.* 129 (11), 2145–2155. doi:10.1242/jcs.181271
- Shen, Y., Jiang, R., Huang, Y., Wang, Y., Zhan, S., Tang, X., et al. (2024). Identification of hub genes through integrated single-cell and microarray transcriptome analysis in osteoarthritic meniscus. *J. Orthop. Surg. Res.* 19 (1), 682. doi:10.1186/s13018-024-05175-z
- Simonds, M. M., Sullivan, K. E., and Brescia, A. C. (2022). Single-cell analysis reveals heterogeneity of juvenile idiopathic arthritis fibroblast-like synoviocytes with implications for disease subtype. *Arthritis Res. Ther.* 24 (1), 225. doi:10.1186/s13075-022-02913-8

- Singh, P., Marcu, K. B., Goldring, M. B., and Otero, M. (2019). Phenotypic instability of chondrocytes in osteoarthritis: on a path to hypertrophy. *Ann. N. Y. Acad. Sci.* 1442 (1), 17–34. doi:10.1111/nyas.13930
- Song, Y., Zhang, C., Omenn, G. S., O'Meara, M. J., and Welch, J. D. (2023). Predicting the structural impact of human alternative splicing. *bioRxiv*, 2023.12.21.572928. doi:10.1101/2023.12.21.572928
- Ule, J., and Blencowe, B. J. (2019). Alternative splicing regulatory networks: functions, mechanisms, and evolution. *Mol. Cell* 76 (2), 329–345. doi:10.1016/j.molcel.2019.09.017
- Vincent, T. L., Alliston, T., Kapoor, M., Loeser, R. F., Troeberg, L., and Little, C. B. (2022). Osteoarthritis pathophysiology: therapeutic target discovery may require a multifaceted approach. *Clin. Geriatr. Med.* 38 (2), 193–219. doi:10.1016/j.cger.2021.11.015
- Wondimu, E. B., Culley, K. L., Quinn, J., Chang, J., Dragomir, C. L., Plumb, D. A., et al. (2018). Elf3 contributes to cartilage degradation *in vivo* in a surgical model of post-traumatic osteoarthritis. *Sci. Rep.* 8 (1), 6438. doi:10.1038/s41598-018-24695-3
- Wu, P., Gao, Y., Shen, S., Xue, Y., Liu, X., Ruan, X., et al. (2019). KHDRBS3 regulates the permeability of blood-tumor barrier via cDENND4C/miR-577 axis. *Cell Death Dis.* 10 (7), 536. doi:10.1038/s41419-019-1771-2
- Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., et al. (2021). clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. *Innovation* 2 (3), 100141. doi:10.1016/j.xinn.2021.100141
- Yammani, R. R., Long, D., and Loeser, R. F. (2009). Interleukin-7 stimulates secretion of S100A4 by activating the JAK/STAT signaling pathway in human articular chondrocytes. *Arthritis Rheum.* 60 (3), 792–800. doi:10.1002/art.24295
- Yan, T., Wang, P., and Cao, Z. (2024). Calcium fructoborate improves knee osteoarthritis in rats by activating hedgehog signaling through DDIT3. *Biol. Trace Elem. Res.* 203, 3803–3819. doi:10.1007/s12011-024-04454-4
- Yu, X., Xu, X., Dong, W., Yang, C., Luo, Y., He, Y., et al. (2022). DDIT3/CHOP mediates the inhibitory effect of ER stress on chondrocyte differentiation by AMPKα-SIRT1 pathway. *Biochim. Biophys. Acta Mol. Cell Res.* 1869 (8), 119265. doi:10.1016/j.bbamcr.2022.119265
- Zeng, G., Xu, Y., Li, Z., and Deng, G. (2025). BCL6 promotes transcription of GPR61 to suppress IL-1β-Induced osteoarthritis progression in C28/I2 cells. *Microbiol. Immunol.* 69 (3), 148–156. doi:10.1111/1348-0421.13195
- Zhang, Y., Han, S., Kong, M., Tu, Q., Zhang, L., and Ma, X. (2021). Single-cell RNA-seq analysis identifies unique chondrocyte subsets and reveals involvement of ferroptosis in human intervertebral disc degeneration. *Osteoarthr. Cartil.* 29 (9), 1324–1334. doi:10.1016/j.joca.2021.06.010
- Zhang, Z., Dong, L., Tao, H., Dong, Y., Xiang, W., Tao, F., et al. (2024a). RNA-binding proteins potentially regulate the alternative splicing of apoptotic genes during knee osteoarthritis progression. *BMC Genomics* 25 (1), 293. doi:10.1186/s12864-024-10181-w
- Zhang, X., Zhang, R., Wang, Y., Li, L., and Zhong, Z. (2024b). CDK5 upregulated by ELF3 transcription promotes IL-1β-induced inflammation and extracellular matrix degradation in human chondrocytes. *Cell Biochem. Biophys.* 82 (4), 3333–3344. doi:10.1007/s12013-024-01415-5
- Zhao, M., Zhang, Y., Li, L., Liu, X., Zhou, W., Wang, C., et al. (2023). KHDRBS3 accelerates glycolysis and promotes malignancy of hepatocellular carcinoma via upregulating 14-3-3ζ. *Cancer Cell Int.* 23 (1), 244. doi:10.1186/s12935-023-03085-4